Advertisement

Topics

AlphaVax, Inc Company Profile

23:07 EST 19th November 2017 | BioPortfolio

AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer and biodefense threats which has the potential to redefine vaccines and the role they play in medicine.
AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines, which have shown excellent protection in multiple models for infectious disease and cancer. Since 1998, the company has raised more than $110 million, with 75% coming from corporate partner and grant funding, and has advanced the alphavaccine platform system from the academic laboratory to human clinical trials, establishing the technical, regulatory, and manufacturing foundation for commercializing alphavaccines.

The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man, and additional trials for other diseases are expected to begin in 2006.

The vaccine market is primed for dramatic growth and the AlphaVax vaccine technology will play a key role in an expanding industry expected to reach $20 billion by 2015.

We are located in Research Triangle Park, North Carolina and employ over 65 staff in a state-of-the-art, 30,000-square-foot research and development facility that includes Bio-Safety Level 2 and 3 (BSL-2/3) laboratories.

Location

P.O. Box 110307
Research Triangle Park
North Carolina
27709-0307
United States of America

Contact

Phone: 919-595-0400
Fax: 919-595-0401
Email: info@alphavax.com


News Articles [0 Results]

None

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

AlphaVax, Inc.

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a proprietary alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the sam...

AlphaVax, Inc

AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer and biodefense threats which has the potential to redefine vaccines and the role they play in...

More Information about "AlphaVax, Inc" on BioPortfolio

We have published hundreds of AlphaVax, Inc news stories on BioPortfolio along with dozens of AlphaVax, Inc Clinical Trials and PubMed Articles about AlphaVax, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AlphaVax, Inc Companies in our database. You can also find out about relevant AlphaVax, Inc Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record